AI Science Tracker

The National and Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha 410081, Hunan, China

1 discovery from 2024

Discoveries

Discovery of anticancer peptides from natural and generated sequences using deep learning

Source check: Needs source check. Not independent scientific confirmation.

Finding: Discovery of anticancer peptides from natural and generated sequences using deep learning. The predictor screened over 3.8 million UniProt sequences and 100,000 generated sequences for anticancer peptides. 37 of 41 candidate peptides inhibited tumor cells in vitro; in vitro and in vivo follow-up reported in the abstract. Evidence limits: Baseline benchmarks are the authors' own; in vivo scope not assessed beyond the abstract. Reviewed from Europe PMC abstract only.

Technology: CNBT-ACPred three-channel deep learning predictor plus a generative model

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
The predictor screened over 3.8 million UniProt sequences and 100,000 generated sequences for anticancer peptides.
Test and result
37 of 41 candidate peptides inhibited tumor cells in vitro; in vitro and in vivo follow-up reported in the abstract.
Limitation / still unknown
Baseline benchmarks are the authors' own; in vivo scope not assessed beyond the abstract.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://europepmc.org/article/MED/39706427

Needs source check · editorial details

The source has not been fully checked or contains conflicting information. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review scope and date are not recorded; source checked does not establish full-text review.

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.